Vivos Therapeutics to Participate in Online Fireside Chat with Water Tower Research on December 16, 2025, at 11 am EST
Vivos Therapeutics (NASDAQ: VVOS) announced that CEO Kirk Huntsman and CFO Brad Amman will join a Water Tower Research fireside chat on December 16, 2025 at 11:00 am ET.
Rhea-AI Summary
Vivos Therapeutics (NASDAQ: VVOS) announced that CEO Kirk Huntsman and CFO Brad Amman will join a Water Tower Research fireside chat on December 16, 2025 at 11:00 am ET.
Management will discuss the company’s strategic business model pivot, operational execution, the market opportunity and competitive environment for sleep-related breathing disorder treatments, and Vivos’ growth and financial strategies. The event is listen-only and requires registration. A replay will be available for 30 days in the Investor Relations section at vivos.com.
Positive
- None.
Negative
- None.
Key Figures
- Fireside chat date
- December 16, 2025
- Scheduled online fireside chat with Water Tower Research
- Event time
- 11:00 am ET
- Scheduled start time for the listen-only fireside chat
- Replay window
- 30 days
- Replay availability period in Investor Relations section
- Current price
- $2.02
- Price prior to fireside chat news, down 1.9% over 24h
- 52-week range
- $1.98–$7.95
- Price positioned just above 52-week low
- Market cap
- $18,605,379
- Equity value prior to the fireside chat announcement
- Today's volume
- 220,429 shares
- Compared with 20-day average volume of 123,785 shares
- Relative volume
- 1.78x
- Pre-news trading activity vs. 20-day average
Historical Context
-
Reported strong Q3 revenue growth driven by SCN acquisition amid operating loss.
-
Announced timing of Q3 2025 financial results release and conference call.
-
Released additional pediatric ADHD and OSA data showing strong improvements with DNA device.
-
Announced landmark pediatric OSA trial with high response and airway volume gains.
-
Reported Q2 revenue decline year over year and higher operating expenses despite SCN acquisition.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
obstructive sleep apnea medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
LITTLETON, Colo., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced that the Company’s CEO Kirk Huntsman and CFO Brad Amman will participate in a fireside chat with Robert Sassoon, senior research analyst of Water Tower Research (“WTR”) on Tuesday, December 16, 2025, at 11:00 am ET.
Vivos management will discuss the strategic business model pivot and operational execution; the market opportunity and competitive environment; and Vivos’ growth and financial strategies.
To register for this listen-only event, please visit:
The replay of the fireside chat will be available for 30 days in the “Investor Relations” section on Vivos’ website at www.vivos.com.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children.
OSA affects over 1 billion people worldwide, yet
Founded in 2016 and based in Littleton, Colorado, Vivos is working to change this. Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.
Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.
For more information, visit www.vivos.com.
Cautionary Note Regarding Forward-Looking Statements
This press release, the online presentation described herein, including statements of the Company’s management and other parties made in connection therewith, contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “would”, “should”, “expects”, “projects,” “potential,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal”. “aim” and variations of such words and similar expressions are intended to identify forward-looking statements. In this press release, forward-looking statements include, without limitation, those relating to (i) the actual future impact of Vivos’ strategic acquisition and alliance model on its future revenues and results of operations and (ii) the anticipated benefits and potential expansion of Vivos’ marketing and distribution model as described herein. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to continue to integrate business from the acquisition and alliance model into its own or otherwise implement sales, marketing and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector; (iv) the risk that Vivos may be unable to secure additional financing to acquire additional sleep centers practices on reasonable terms when needed, if at all, or maintain its Nasdaq listing, (v) market and other conditions that could impact Vivos’ business or ability to obtain financing, and (vi) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Media Inquiries:
Jennifer Hauser, Executive Assistant to the CEO
Investor Relations Contact
investors@vivoslife.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.